Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors

Molecular Cancer Therapeutics

Volumn 5, Issue 12, 2006, Pages 3105-3112

  Kulimova, Emma ^a   Oelmann, Elisabeth ^a   Bispling, Guido ^a   Kienast, Joachim ^a   Mesters, Rolf M ^a   Schwäble, Joachim ^a   Hilberg, Frank ^b   Roth, Gerald J ^c   Munzert, Gerd ^c   Stefanic, Martin ^c   Steffen, Björn ^a   Brandts, Christian ^a   Müller Tidow, Carsten ^a   Kolkmeyer, Astrid ^a   Büchner, Thomas ^a   Serve, Hubert ^a   Berdel, Wolfgang E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIBF 1000; BIBF 1120; CD135 ANTIGEN; CYTARABINE; FIBROBLAST GROWTH FACTOR; INDOLINONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CULTURE; CANCER INHIBITION; CANCER RESISTANCE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; METABOLIC INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TANDEM REPEAT;

ACUTE DISEASE; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYTARABINE; HUMANS; INDOLES; LEUKEMIA, MYELOID; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33846244201     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0323     Document Type: Article

References (27)

1. Dilly SA, Jagger CJ. Bone marrow stromal cell changes in haematological malignancies. J Clin Pathol 1990;43:942-6.
2. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased agiogenesis in patients with acute myeloid leukemia. Blood 2000;95: 309-13.
3. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95: 2637-44.
4. Fiedler F, Graeven U, Ergun S, at al. VEGF, a possible paracrine growth factor in human AML. Blood 1997;89:1870-5.
5. Foss B, Ulvestad E, Bruserud O. Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. Eur J Haematol 2001;67:267-78.
6. Bieker R, Pedro T, Kramer J, et al. Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukaemia. Cancer Res 2003; 63:7 241-6.
7. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcl-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
8. Fiedler W, Mesters R, Tinnefeld H, at al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003; 102:2763 - 7.
9. Mesters RM, Padro T, Bieker R, at al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001;98:241 -3.
10. O'Farrell A-M, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of flt3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9:5465 - 76.
11. Hell-Pourmojib M, Hilberg F, Roth G, Heckel A, van Meel JCA. BIBF1000: a novel and potent VEGFR-2 inhibitor inhibits proliferation and induces apoptosis of endothelial cells in vitro. Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Joint AACR-NCI-EORTC International Conference, October 29 to November 2, 2001, Miami Beach, Florida.
12. Hilberg F, Tontsch-Grunt U, Colbatzky F, et al. BIBF 1120 - a novel, small molecule triple angiokinase inhibitor: profiling as a clinical candidate for cancer therapy. Molecular Targets and Cancer Therapeutics, 16th EORTC-NCI-AACR Symposium, September 28 to October 1, 2004, Geneva, Switzerland.
13. Topp MS, Koenigsmann M, Mire-Sluis A, et al. Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood 1993;82:2837-44.
14. Topp MS, Papadimitriou CA, Eitelbach F, et al. Recombinant human interleukin-4 has antiproliferative activity on human tumor cell lines from epithelial and nonepithelial histologies. Cancer Res 1995;55: 2173-6.
15. Oelmann E, Kraemer A, Serve H, et al. Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. Int J Cancer 1997;71:1066-76.
16. Freedman VH, Shin S. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 1974;3:355-9.
17. Gross JL, Behrens DL, Mullins DE, Kornblith PL, Dexter DL. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res 1988;48:291-6.
18. Von Hoff DD. He's not going to talk about in vitro predictive assays again, is he? (Commentary). J Natl Cancer Inst 1990;82:96-101.
19. Von Hoff DD, Sandbach JF, Clark GM, et al. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 1990;82:110-6.
20. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the ras and stat5 pathways. Blood 2000;96:3907-14.
21. Mizuki M, Schwäble J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003;101:3164-73.
22. Lentzsch S, Chatterjee M, Gries M, et al. P13-K/AKT/FKHR and MAPK signalling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004;18:1883-90.
23. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukaemia with t(5;12) chromosomal translocation. Cell 1994;77:307-16.
24. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1Ll genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-14.
25. Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFa fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879 - 91.
26. Chen J, DeAngelo DJ, Kutok JL, at al. PKC41 2 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in the treatment of stem cell myeloproliferative disorder. Proc Natl Aced Sci U S A 2004; 101: 14479-84.
27. Mross K, Baas F, Medinger M, et al. A clinical phase 1, pharmacokinetik (PK), and pharmacodynamic (PD) study of BIBF 1120 in advanced cancer patients. Molecular Targets and Cancer Therapeutics, 16th EORTC-NCI-AACR Symposium, September 28 to October 1, 2004, Geneva, Switzerland.